Format

Send to

Choose Destination
Exp Eye Res. 2018 Mar;168:49-56. doi: 10.1016/j.exer.2018.01.003. Epub 2018 Jan 8.

Novel everolimus-loaded nanocarriers for topical treatment of murine experimental autoimmune uveoretinitis (EAU).

Author information

1
Department of Ophthalmology and Ophtha-Lab at St. Franziskus Hospital, Muenster, Germany. Electronic address: maren.kasper@uveitis-zentrum.de.
2
Apidel SA, Geneva, Switzerland.
3
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
4
Department of Ophthalmology and Ophtha-Lab at St. Franziskus Hospital, Muenster, Germany.
5
Department of Ophthalmology, Clinic for Diseases of the Anterior Segments of the Eyes, Essen University Hospital, Essen, Germany; Institute for Experimental Ophthalmology, University of Muenster, Germany.
6
Department of Dermatology, University of Muenster, Germany.
7
Institute for Experimental Ophthalmology, University of Muenster, Germany.
8
Apidel SA, Geneva, Switzerland; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
9
Department of Ophthalmology and Ophtha-Lab at St. Franziskus Hospital, Muenster, Germany; University of Duisburg-Essen, Essen, Germany.

Abstract

In the present study, therapeutic effect of topically applied everolimus (EV)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly (lactic acid) (mPEGhexPLA) nanocarriers on experimental autoimmune uveoretinitis (EAU) were investigated. EAU was induced in B10.RIII mice via immunization with human interphotoreceptor retinoid-binding protein peptide 161-180 (hIRBPp161-180) in complete Freund's adjuvant. Everolimus-loaded mPEGhexPLA (EV/mPEGhexPLA) nanocarriers were prepared by using a solvent evaporation method. On days 12-21 postimmunization (p.i.), the right eyes were treated five times daily either with 10 μl of 0.5% everolimus formulation or PBS (control). The EAU score of the eyes was determined histologically. On day 21 p.i., the peripheral immune responses were measured in serum, cervical lymph nodes (LN), and spleens via hIRBPp161-180-specific serum antibodies, cytokine secretion (ELISA), lymphocyte proliferation, and FoxP3+ regulatory T cells (Treg; flow cytometry). Compared to the PBS-treated mice, unilateral topical everolimus treatment significantly reduced EAU severity in both eyes (p < .05). The treatment reduced the antigen (Ag)-specific hIRBPp161-180-induced proliferation (p < .05), IL-2, IL-17, and IFN-γ secretion from cells isolated from the left and right cervical LN (p < .05). Under everolimus treatment, IL-10 secretion and CD4+CD25+FoxP3+ Treg frequency from cervical LN were enhanced. The proliferative response and cytokine secretion as well as the frequency of splenic Treg were almost unchanged. Topical administration of an everolimus formulation improved EAU in both eyes. The effect might also be related to systemic immunosuppressive effects, as several systemic cellular immune responses were influenced.

KEYWORDS:

Drug delivery; Everolimus; Micelles; Nanocarrier; Ophthalmics; Regulatory cells; Uveitis; mTOR inhibitors

PMID:
29326066
DOI:
10.1016/j.exer.2018.01.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center